



AMRI and Codexis Announce Technology Collaboration

February 13, 2013

SMARTSOURCING™ Partnership to Focus on Improved Process Development

[Download PDF](#)

Albany, NY and Redwood City, CA (February 13, 2013) — AMRI (NASDAQ: AMRI) and Codexis (NASDAQ: CDXS) announced today that they have entered into a SMARTSOURCING™ partnership. The collaboration will provide opportunities to combine the two companies' capabilities and technologies for specific customer projects, yielding increased value to customers in the form of potentially lower costs, greater yields, cleaner processes and/or faster turnaround times.

Under this non-exclusive, two-year agreement, the companies will align their respective strengths to identify and implement new and improved manufacturing routes for selected Active Pharmaceutical Ingredients (APIs). Combining Codexis' directed evolution technology that enables rapid enzyme discovery and optimization with AMRI's process development and manufacturing capabilities, including utilizing AMRI's proprietary microbial strains, creates synergies that will broaden both companies' ability to offer customers' cost-effective, efficient, and sustainable manufacturing processes.

"We are pleased to announce this partnership with Codexis, a company that shares our philosophy of prioritizing scientific problem solving, innovation and customer service," said AMRI's Chairman, President and CEO, Thomas E. D'Ambra, Ph.D. "Combining AMRI's expertise in chemistry, biocatalysis, quality assurance and manufacturing with Codexis' cutting-edge biocatalysis technology and services, creates a proprietary advantage to our customer's development projects. This is another example of the AMRI SMARTSOURCING™ strategy of creating partnerships to deliver better outcomes to our customers."

"Codexis selected AMRI for this collaboration because AMRI understands the opportunity to use biocatalysis for effective and comprehensive route assessment and manufacturing," says Dr. Peter Seuffer-Wasserthal, SVP Pharmaceuticals, Codexis Inc. "Both companies have established strong reputations in the pharmaceutical manufacturing industry. By working together, AMRI and Codexis should identify more opportunities, which will benefit both companies and their customers by developing innovative, cost-effective and practical chemical processes."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at <http://www.amriglobal.com/> or follow us on Twitter (@amriglobal).

About Codexis Inc.

Codexis, Inc. is a developer of world-leading enzymes and processes for the production of pharmaceuticals, biofuels and bio-based chemicals. Codexis' product lines include CodeXyme™ cellulase enzymes and CodeXol™ detergent alcohol. Partners and customers include global leaders such as Merck, Pfizer and Arch Pharmalabs. For more information, see www.codexis.com.

Contacts

AMRI

Investors: [Michael Nolan](#), AMRI Chief Financial Officer, 518-512-2261

Media: [Gina Monari](#), AMRI Communications, 518-512-2512

Codexis, Inc.

Investors: 212-362-1200, ir@codexis.com

Media: media@codexis.com